子宫内膜异位症患者血清中ENA-78的表达

目的 研究上皮细胞来源的中性粒细胞激活肽(ENA-78)在子宫内膜异位症发病中的作用。方法 应用ELISA法,检测42例子宫内膜异位症患者(Ⅰ~Ⅱ期20例、Ⅲ~Ⅳ期22例)血清ENA-78的浓度,并与25例非子宫内膜异位症患者(对照组)进行比较。结果 子宫内膜异位症组血清中ENA-78浓度明显高于对照组(2.97±1.91ng/ml vs 0.72±0.24ng/ml,P<0.001),Ⅲ、Ⅳ期比Ⅰ、Ⅱ患者血清中ENA-78增高更明显(4.48±1.25ng/mlvs1.30±0.74ng/ml,P<0.001)。增殖期与分泌期比较,两组血清ENA-78的表达均无显著差异。结论 子宫内膜异位症患者ENA-78明显升高,可能为子宫内膜异位症发病的因素之一。

Changes of serum epithelial neutrophil-activating peptide-78 in patients with endometriosis

Objective To investigate the role of serum epithelial neutrophil-activating peptide-78 (ENA-78) in the pathogenesis of endometriosis. Methods Serum concentrations of ENA-78 were measured by means of enzyme-linked immunosobent assay (ELISA) in 42 patients with endometriosis (20 in stages Ⅰand Ⅱ and 22 in stages Ⅲ and Ⅳ) in comparison with 25 women without endometriosis (control group). Results Serum concentrations of ENA-78 were significantly higher in endometriosis group than in the control group (2.97±1.91 ng/ml vs 0.72±0.24 ng/ml, P<0.001), and ENA-78 levels in stages Ⅲ and Ⅳ were significantly higher than those in stagesⅠ and Ⅱ (4.48±1.25 ng/ml vs 1.30±0.74 ng/ml, P<0.001). Significant difference in ENA-78 levels between follicular phase and luteal phase was found in neither of the groups. Conclusion Patients with endometriosis have elevated serum ENA-78 levels, which might be a pathogenic factor of endometriosis.